Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2717-2721

  Sugie, Satoru ^a   Tsukino, Hiromasa ^a   Mukai, Shoichiro ^a   Akioka, Takahiro ^b   Shibata, Norihiko ^b   Nagano, Masafumi ^b   Kamoto, Toshiyuki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Fujimoto Hospital   (Japan)

Author keywords

Carcinogenesis; Cyclooxygenase2 (COX2); Polymorphism; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; GLEASON SCORE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOOXYGENASE 2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84899088228     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1358-y     Document Type: Article

References (27)

1. Committee for Establishment of the Guidelines on Screening for Prostate Cancer. Japanese Urological Association: updated Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol. 2010;17(10):830-8.
2. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217-26.
3. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127-9.
4. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-18.
5. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093-9.
6. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137:194-9.
7. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1995;1299:125-40.
8. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-66.
9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-73.
10. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557-61.
11. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25:961-6.
12. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668-72.
13. Fernandez P, de Beer PM, van der Merwe L, Heyns CF. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis. 2008;29:2347-50.
14. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C. 2004;129:65-73.
15. Bau DT, Tsai MH, Huang CY, Lee CC, Tseng HC, Lo YL, et al. Relationship between polymorphisms of nucleotide excision repair genes and oral cancer risk in Taiwan: evidence for modification of smoking habit. Chin J Physiol. 2007;50:294-300.
16. Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, Tsai CW, et al. Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res. 2009;29:3903-7.
17. Wu GY, Hasenberg T, Magdeburg R, Bönninghoff R, Sturm JW, Keese M. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg. 2009;33:124-9.
18. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73-8.
19. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565-76.
20. Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70:908-15.
21. Chiang SL, Chen PH, Lee CH, Ko AM, Lee KW, Lin YC, et al. Up-regulation of inflammatory signallings by areca nut extract and role of cyclooxygenase-2 -1195G>A polymorphism reveal risk of oral cancer. Cancer Res. 2008;68:8489-98.
22. Peters WH, Lacko M, Te Morche RH, Voogd AC, Oude Ophius MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009;31:938-43.
23. Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, Lin HH, et al. Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan. Anticancer Res. 2011;31(1):221-5.
24. Mandal RK, Mittal RD. Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res. 2011;42(7):620-6.
25. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer. 2007;121:1325-30.
26. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66:7370-7.
27. Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, et al. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer. 2006;119:398-405.